BiomarkersHumans
Differential performance of plasma p ‐tau217 in detecting intermediate vs high Alzheimer's disease neuropathologic change
AAIC 2025 Abstract
Abstract
Background: In vivo detection of intermediate and high Alzheimer's disease neuropathologic changes (ADNC) is key for disease staging and clinical trial enrolment. While a visually positive tau‐PET scan with the FDA/EMA‐approved tracer [ ¹⁸ F]flortaucipir can be considered a reliable proxy of high ADNC (Fleisher et al.
